Add this topic to your myFT Digest for news straight to your inbox
National security concerns in Washington threaten company that derives majority of its revenues from the US
Officials warn weaknesses in surveillance will hinder vaccine development as countries struggle to agree accord
Eli Lilly and Novo Nordisk’s weight-loss drugs have transformed their fortunes but a backlash could be looming
Retail group agrees first partnership with a big drug company since launching online pharmacy business in 2020
Booming sector raises tough questions for ESG investors
We risk forgetting the lessons of the Covid pandemic
Breakthrough medicine will now be subject to further review by committee of independent experts
Drugmaker releases promising trial results for a pill and expects to enter China this year
Chief executive of aspirin-to-Roundup group has limited options to sort fallout of ill-fated Monsanto purchase
Avid Bioservices had an oopsie
There is still room for growth in Japan’s $53bn dispensing pharmacy market
The company’s deleveraging route looks long and distinctly uncertain
Bill Anderson quashes speculation after suspending break-up of indebted German drugs-to-pesticides group
Bill Anderson expects further profit declines at the aspirin-to-agriculture conglomerate in 2024
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
New Pasteur Institute head highlights risks posed by shortages of money, staff and political goodwill
GHO Capital has put contract research group FairJourney Biologics up for sale
Pharmaceutical companies scale back development in aftermath of pandemic
Struggling German chemicals group announces boardroom reshuffle ahead of update on potential break-up
Spinning off consumer health is no easy fix but a sale would offer a quicker turnaround
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
German pharma group finds no unexpected side effects during trial, including at higher doses
Baseimmune aims to predict future pathogen mutations to create jabs that will be effective for longer
Infections quadruple from last year after warnings that warming temperatures will increase cases
International Edition